Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

Recent News

Dual-Target CAR T-Cell Therapy in Resistant Multiple Myeloma
NCI-MATCH Trial Subprotocol: T-DM1 in HER2-Positive Salivary Gland Tumors
Priority Review Granted by FDA to Immunotherapy Combination in Lung Cancer
FDA Grants Priority Review to Olaparib/Bevacizumab as Maintenance Therapy for Ovarian Cancer
Early-Phase Results With CD19-Directed Immunotherapy for CLL
Novel Monoclonal Antibody in Relapsed or Refractory Multiple Myeloma
Early Results With Chemotherapy-Free Triplet Regimen in Resistant CLL
Pertuzumab Plus Standard Treatment in HER2-Positive Early Breast Cancer
KEYNOTE-522 in Triple-Negative Breast Cancer: Pathologic Complete Response Rates With Pembrolizumab
‘Priming’ Patients With Advanced Melanoma for Retreatment With Checkpoint Inhibitors
Two-Year Survival Results With Neoadjuvant T-VEC in Resectable Melanoma
ASH 2019: Dose-Finding Study of Novel Immunotherapy for Resistant Myeloma
SMR 2019: T-VEC Plus Ipilimumab in Advanced Melanoma
KEYNOTE-048 Opens Door Farther for Pembrolizumab in Head/Neck Cancer
Can Skin Reactions Portend Clinical Benefit in Patients With NSCLC?
ASH 2019: Early Trial Results With CAR T-Cell Therapy for Resistant Myeloma
ESMO I-O 2019: Overall Survival With Nivolumab/Ipilimumab in Lung Cancer
Current and Future Role of Immunotherapy in Cutaneous Squamous Cell Carcinoma
SABCS 2019: Margetuximab Versus Trastuzumab in HER2-Positive Metastatic Breast Cancer
SMR 2019: Nivolumab Plus Ipilimumab and Nivolumab Alone in Advanced Melanoma
ASH 2019: Updated Trial Results With Ibrutinib and Rituximab in CLL
IKCS 2019: Novel ImmunoPET/CT Under Study in Renal Cell Carcinoma
SMR 2019: Vaccine Under Study to Prevent Recurrence in High-Risk Advanced Melanoma
SABCS 2019: Tucatinib-Based Therapy for HER2-Positive Metastatic Breast Cancer
ASH 2019: CANDOR Trial of Daratumumab Combination Therapy for Resistant Myeloma
ASH 2019: Acalabrutinib Combination Therapy and Monotherapy in Treatment-Naive CLL
ABC Trial: Nivolumab Plus Ipilimumab for Melanoma Brain Metastases
ASH 2019: Early Results With Multiplexed Genetic Engineering in Treating Multiple Myeloma
Atezolizumab/Chemotherapy Approved by FDA in First-Line Treatment of Metastatic Lung Cancer
Case Studies: Possible Link Between Nivolumab for Lung Cancer and Pericardial Effusion
IKCS 2019: Lenvatinib Plus Pembrolizumab in Subset of Patients With Kidney Cancer
Triplet Regimen for BRAF-Mutated Metastatic Melanoma
Final Overall Survival With Atezolizumab/Chemotherapy in Advanced Lung Cancer
IKCS 2019: Treatment-Free Survival With Immunotherapy Versus Sunitinib in Kidney Cancer
Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.